NEW DELHI : Biotechnology major Biocon and drug firm Mylan on Tuesday announced the launch of Fulphila , a biosimilar pegfilgrastim, in Canada after getting approval from the health regulator. "This is the second biosimilar from our portfolio to be launched in Canada by our partner Mylan and is an endorsement of our science, development and manufacturing capabilities in the area of biologics," Biocon Biologics CEO Christiane Hamacher said.
Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs, the companies said in a joint statement. "Fulphila is the second biosimilar to be offered by